非特指外周T细胞淋巴瘤的治疗展望

The improvement of therapy in peripheral T-cell lymphoma,not otherwise specified

非特指外周T细胞淋巴瘤(PTCL)是一类在生物学和临床上均有高度异质性的疾病,其诊断建立在除外WHO已定义的PTCL其他亚型,基因表达谱分析提高了非特指外周T细胞淋巴瘤的诊断能力。尽管因一线治疗方案尚不确定,以CHOP为代表的含蒽环类药物的方案继之以自体造血干细胞移植,是目前适合移植患者的标准选择。新药已经被证实在复发和难治患者中有效,但并不改善生存率。这些新药是否能与CHOP联合作为新的一线治疗方案的研究正在进行。

Peripheral T-cell lymphoma,not otherwise specified（PTCL-NOS）is a biologically and clinically heterogeneous disease.PTCL-NOS is diagnosed on an exclusion basis as a disease whose features are not consistent with any of the other PTCL subtypes defined by the World Health Organization classification.Gene expression profiling has improved the diagnosis of PTCL-NOS.Although the best first-line approach is not to be defined,anthracycline-containing regimens,mainly CHOP,followed by auto SCT are regarded as the standard in transplant-eligible patients.Several new drugs are active in relapsed and refractory patients,although these drugs do not significantly affect survival rates.Whether these drugs can be safely and efficiently combined with CHOP in newer first-line regimens is under investigation.